Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 30679. Отображено 100.
05-01-2012 дата публикации

Anti-inflammatory dissolvable film

Номер: US20120003292A1
Принадлежит: Individual

Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom.

Подробнее
19-01-2022 дата публикации

Раневая атравматическая повязка для животных

Номер: RU0000208882U1

Полезная модель относится к ветеринарной медицине, в частности, к ветеринарной хирургии, и предназначена для лечения инфицированных ран, язв, пролежней, гнойничковых и трофических поражений кожи и подкожной клетчатки и может использоваться как перевязочное средство. Отличительной особенностью раневой атравматической повязки является то, что ее внутренний рабочий слой, обращенный к раневой поверхности, состоит из мелкоячеистого хлопкового нетканого полотна, предварительно обработанного раствором риванола и тримекаина с последующим высушиванием и нанесением на нее антисептика стимулятора Дорогова второй фракции (АСД-2ф), микрокапсулированного в оболочку из натрий карбоксиметилцеллюлозы. Наружный слой повязки, покрывающий слой микрокапсул, состоит из тонкой пергаментной бумаги и нетканого полотна. При этом свободные от слоя микрокапсул края повязки по периметру склеиваются. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 208 882 U1 (51) МПК A61K 31/00 (2006.01) A61K 9/70 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК A61K 31/00 (2021.08); A61K 9/70 (2021.08) (21)(22) Заявка: 2021125236, 25.08.2021 (24) Дата начала отсчета срока действия патента: Дата регистрации: 19.01.2022 (45) Опубликовано: 19.01.2022 Бюл. № 2 2 0 8 8 8 2 R U (54) Раневая атравматическая повязка для животных (57) Реферат: Полезная модель относится к ветеринарной медицине, в частности, к ветеринарной хирургии, и предназначена для лечения инфицированных ран, язв, пролежней, гнойничковых и трофических поражений кожи и подкожной клетчатки и может использоваться как перевязочное средство. Отличительной особенностью раневой атравматической повязки является то, что ее внутренний рабочий слой, обращенный к раневой поверхности, состоит из мелкоячеистого хлопкового нетканого полотна, предварительно Стр.: 1 (56) Список документов, цитированных в отчете о поиске: RU 99711 U1, 27.11.2010. RU 2031648 C1, 27.03.1995. CN 109419810 A, 05.03.2019. PE 20081883 A1, ...

Подробнее
09-02-2012 дата публикации

Solid preparation

Номер: US20120034276A1
Принадлежит: Aska Pharmaceutical Co Ltd, Lintec Corp

A solid preparation 1 comprises a drug-containing unit 2 containing a cationic drug, and a gel-forming layer 4 , containing an anionic polymer, for covering the drug-containing unit 2 and forming a gel with absorbing water, and optionally an intermediate layer 3 interposed between the drug-containing unit 2 and the gel-forming layer 4 . The solid preparation 1 improves the elution property of the drug by incorporating an acidic component (such as tartaric acid or citric acid) into the intermediate layer 2 and/or the intermediate layer 3 . The gel-forming layer 4 may comprise a carboxyvinyl polymer and a polyvalent metal compound. The gel-forming layer 4 may be covered with a surface layer (anti-adhesive layer) 5.

Подробнее
16-02-2012 дата публикации

Novel biomaterials, their preparation and use

Номер: US20120040901A1
Принадлежит: Individual

The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: 1. contacting the anionic polymeric component and an cyclodextrin component in an aqueous medium, and 2. adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cyclodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compounds, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.

Подробнее
08-03-2012 дата публикации

Transdermal Preparation

Номер: US20120058175A1
Принадлежит: Hisamitsu Pharmaceutical Co Inc

Provided is a transdermal preparation, which is capable of long-term (1-day to 7-day) release of a basic drug from a preparation, continuously and at a consistent concentration; shows little reduction over time in the drug content, even if multiple drugs are contained in the preparation; and is produced by a simple process. The transdermal preparation comprises a substrate, and an adhesive layer containing a basic drug and a water-soluble polymer.

Подробнее
15-03-2012 дата публикации

Preparation for external application

Номер: US20120064011A1
Автор: Dirk Schumann
Принадлежит: Bubbles and Beyond GmBH

Preparations for external application to human and animal skin, comprising: a) a composition in the form of a fluid nanophase system, comprising the components of a1) at least one water-insoluble substance with a water solubility of less than 4 gram per liter, a2) at least one amphiphilic substance (NP-MCA), which has no surfactant structure, does not build structures alone, the solubility of which is between 4 g and 1000 g per liter in water or oil and which does not enrich preferably at the oil-water interface, a3) at least one anionic, cationic, amphoteric and/or non-ionic surfactant, a4) at least one polar protic solvent, in particular having hydroxy functionality, a5) if necessary one or more adjuvants, wherein the percentage relate to the total weight of the composition each; and b) a therapeutic, cosmetic or diagnostically effective agent in a therapeutic, cosmetic or diagnostically effective amount.

Подробнее
05-04-2012 дата публикации

Multi-layer tissue systems and methods

Номер: US20120083900A1
Принадлежит: AlloSource Inc

Embodiments of the present invention encompass anti-adhesion wound dressings including patches made from amnion tissue obtained from human birth tissue. Exemplary amnion patches can be fabricated by folding a section of amnion over on itself with the epithelial layer on the outside of the folded patch and the fibroblast layer on the inside of the folded patch. Optionally, individual amnion tissue pieces can be sandwiched together to provide a multi-layer patch. Sufficient pressure is applied to the layered amnion to cause adherence between opposing faces of the fibroblast layers. The pressed fibroblast layers provide mechanical strength to hold the amnion patch together with the epithelial layers on the outsides of the amnion patch.

Подробнее
12-04-2012 дата публикации

Antiviral transdermal patch and method for producing the same

Номер: US20120089104A1
Принадлежит: Individual

An antiviral transdermal patch including a backing layer, a viscous polymer layer, and a protection film layer. The viscous polymer layer includes an antiviral agent, a viscous polymer, and a transdermal enhancer. The transdermal enhancer is laurocapram or a mixture thereof. The antiviral agent is a nucleoside antiviral drug with a daily delivery rate of less than 100 mg/day. The patch effectively promotes the penetration of a nucleoside antiviral agent into the blood circulation and avoids enzymolysis in the gastrointestinal tract and the first pass effect of the liver and reduces side effect of drugs, thereby inhibiting the replication of target viruses and reducing viral DNA level in the serum. A method for producing the patch is also provided. The raw materials involved in the invention are easily purchased from the market at a low cost.

Подробнее
19-04-2012 дата публикации

Adhesive patch-containing package bag and method for storing adhesive patch

Номер: US20120090275A1
Принадлежит: Hisamitsu Pharmaceutical Co Inc

The present invention relates to an adhesive patch-containing package bag 1, having: a package bag 8; and an adhesive patch 10 stored inside the package bag 8, wherein the adhesive patch 10 has a backing 12, an adhesive layer 14 laminated on at least one side of the backing 12 and containing ropinirole and/or a pharmaceutically acceptable salt thereof, and a release liner 16 covering the adhesive layer 14, and a relative humidity at 4° C. is maintained at 35% or higher inside the package bag 8.

Подробнее
19-04-2012 дата публикации

Opioid Composition for Treating Skin Lesions

Номер: US20120093929A1
Принадлежит: Euro Celtique SA

The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.

Подробнее
26-04-2012 дата публикации

Compositions and methods for biological remodeling with frozen particle compositions

Номер: US20120101738A1
Принадлежит: SEARETE LLC

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Подробнее
03-05-2012 дата публикации

Pharmaceutical formulation containing gelling agent

Номер: US20120108622A1
Принадлежит: Purdue Pharma LP

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
24-05-2012 дата публикации

Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid

Номер: US20120128754A1
Автор: Edward Tak Wei
Принадлежит: Individual

The present invention pertains generally to the field of ocular treatment, and more specifically to the use of a liquid cooling agent composition comprising a cooling agent for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) eye discomfort. The preferred cooling agent is (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarboxylic acid 2,3-dihydroxy-propyl ester (referred to herein as CPS-030). The liquid cooling agent composition is topically administered to at least a portion of the external surface of the eyelid (preferably the closed eyelid) of the eye to be treated. Preferably, the liquid cooling agent composition is carried on or in a wipe, pad, or towelette, for example, an eye wipe.

Подробнее
24-05-2012 дата публикации

Destructive Disposal of Medical Active Ingredients in Transdermal Therapeutic Systems

Номер: US20120129415A1
Автор: Margit Wirz, Thomas Hille
Принадлежит: Individual

The invention relates to a multilayered structure used in the destructive disposal of medical active ingredients contained in transdermal therapeutic systems (=TTS). The structure has a multi-layer design and contains at least one layer having agents embedded therein and at least one fiber layer. It may additionally include a protective layer. The structure according to the invention is stored separately from the TTS. The separately stored structure is brought into contact with the TTS after use of the TTS.

Подробнее
14-06-2012 дата публикации

Binary and tertiary galvanic particulates and methods of manufacturing and use thereof

Номер: US20120148633A1

The present invention relates to galvanic particulates, their methods of manufacture and uses in treatments are described. The galvanic particulates may be binary or tertiary galvanic particulates, for example, containing multiple layers or phases of conductive materials.

Подробнее
28-06-2012 дата публикации

Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same

Номер: US20120164245A1
Принадлежит: Individual

Use of high doses above 1 gm per day of ascorbic acid or the derivatives thereof for the treatment of neurodegenerative and neuro-muscular degenerative diseases and disorders, in particular amytrophic lateral sclerosis, multiple sclerosis, alzheimer's disease, parkinson's disease, and muscular dystrophy is disclosed. Preferably the dose includes mannitol which facilitates the delivery of ascorbic acid to the target cells in the brain. Still further the said dose includes zinc citrate for preventing formation of kidney stones. Dose compositions for various routes of application such as oral, intravenous, intramuscular, nasal and in the form of transdermal patches are discussed.

Подробнее
28-06-2012 дата публикации

Transdermal drug delivery device including an occlusive backing

Номер: US20120165762A1
Принадлежит: Noven Pharmaceuticals Inc

A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.

Подробнее
05-07-2012 дата публикации

Percutaneous absorption type plaster

Номер: US20120171278A1
Принадлежит: Hisamitsu Pharmaceutical Co Inc

A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2 , wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is 1/3 times by mass to 4 times by mass as that of the rosin-based resin.

Подробнее
12-07-2012 дата публикации

Electrophoretic display

Номер: US20120176663A1
Автор: HongMei Zang, Hui Chen
Принадлежит: Individual

The present invention is directed to an electrophoretic display comprising: (a) microcups comprising partition walls and top-openings; (b) an organic-based electrophoretic fluid filled in the microcups, wherein said fluid comprises charged pigment particles dispersed in a solvent; and (c) a top-sealing layer formed from a sealing composition to enclose the electrophoretic fluid within the microcups. The sealing composition comprises: (i) a water soluble polymer, (ii) a water-based suspension, a water-based dispersion, a water-based emulsion, or a water-based latex, each comprising a polymer; and (iii) water.

Подробнее
02-08-2012 дата публикации

Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions

Номер: US20120196877A1
Автор: Nikhilesh N. Singh
Принадлежит: Transcept Pharmaceuticals Inc

The present invention provides novel compositions comprising a combination of a 5-HT 3 receptor antagonist and a selective dopamine D 2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT 3 receptor antagonist ondansetron and a selective dopamine D 2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subject's obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.

Подробнее
09-08-2012 дата публикации

Transdermal delivery patch

Номер: US20120201891A1
Принадлежит: Phosphagenics Ltd

A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.

Подробнее
16-08-2012 дата публикации

Pad for herbal medicine in which release of medicinal ingredient can be controlled, and manufacturing method thereof

Номер: US20120209056A1
Автор: Hi Gu Kim
Принадлежит: BM BIOTECHNOLOGY LAB CO Ltd

The present disclosure relates to a method for manufacturing a pad for herbal medicine in which the release of medicinal ingredients can be controlled, which comprises: separating two or more medicinal herbal ingredients prescribed or prepared according to pharmacological effects on the basis of the weight ratio of each medicinal ingredient to total weight of the medicinal ingredients; grinding the medicinal ingredients separated on the basis of weight ratio, wherein fine particles are ground to different sizes according to the setting of release duration; preparing herbal medicine by mixing the ground medicinal ingredients together, and then mixing the ingredients with a binding agent; and adhering the herbal medicine to a base sheet. The pad for herbal medicine manufactured according to the method allows for persistent permeation of medical ingredients through the skin with different release rate for each medicinal ingredient, and thus, the efficacy of the medicinal ingredient layer and the effect of treating disease can be maximized.

Подробнее
16-08-2012 дата публикации

Transdermal therapeutic system for administration of fentanyl or an analog thereof

Номер: US20120209223A1
Принадлежит: Acino AG

Disclosed is a transdermal therapeutic system for administering an active ingredient through the skin comprising: a) a back layer, b) a reservoir on the back layer comprising b1) a first layer containing active ingredient, at least one gel former, at least one plasticizer, and a first polyisobutylene; and b2) a second layer containing active ingredient, at least one gel former, at least one plasticizer, and a second polyisobutylene, wherein the first polyisobutylene is different from the second polyisobutylene, wherein at least the first layer contains undissolved active ingredient in the form of active ingredient particles; and wherein the active ingredient is fentanyl or an analogue of the fentanyl.

Подробнее
23-08-2012 дата публикации

Immunoneutral silk-fiber-based medical devices

Номер: US20120210547A1
Принадлежит: Allergan Inc

Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties.

Подробнее
23-08-2012 дата публикации

Methods of making and using compositions comprising flavonoids

Номер: US20120213842A1
Автор: Philip J. Birbara
Принадлежит: Individual

The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

Подробнее
23-08-2012 дата публикации

Composition for promoting wound healing

Номер: US20120213843A1
Принадлежит: LIPIDOR AB

A lipid layer forming wound healing promoting composition comprising volatile silicone oil, polar lipid, C 2 -C 4 aliphatic alcohol, and a wound healing agent, in particular a low to medium size natural or synthetic peptide. Also disclosed is a method of forming the lipid layer on a wound and a medical patch provided with the composition.

Подробнее
23-08-2012 дата публикации

Topical formulations comprising a steroid

Номер: US20120214776A1

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Подробнее
27-09-2012 дата публикации

Mesh enclosed tissue constructs

Номер: US20120244617A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Described is a scaffold that is strong enough to resist forces that exist inside a body, while possessing biocompatible surfaces. The scaffold is formed of a layer of mesh (e.g., Stainless Steel or Nitinol) that is tightly enclosed by a multi-layer biological matrix. The biological matrix can include three layers, such a first layer (smooth muscle cells) formed directly on the metal mesh, a second layer (fibroblast/myofibroblast cells) formed on the first layer, and a third layer (endothelial cells) formed on the second layer. The scaffold can be formed to operate as a variety of tissues, such as a heart valve or a vascular graft. For example, the mesh and corresponding biological matrix can be formed as leaflets, such that the scaffold is operable as a tissue heart valve.

Подробнее
11-10-2012 дата публикации

Device for transdermal administration of drugs including acrylic polymers

Номер: US20120258942A1
Автор: David Kanios
Принадлежит: Noven Pharmaceuticals Inc

A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.

Подробнее
11-10-2012 дата публикации

Transdermal therapeutic systems containing 4-n-butylresorcinol

Номер: US20120259020A1
Принадлежит: Beiersdorf AG

Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient.

Подробнее
18-10-2012 дата публикации

Dual lane coating

Номер: US20120263865A1
Автор: Beuford A. Bogue
Принадлежит: MONOSOL RX LLC

The present invention relates to methods and apparatuses for forming an active-containing film product, while significantly reducing the amount of wasted active material. The resulting product is an active-containing film product that meets the user's predetermined criteria of physical properties and is suitable for use.

Подробнее
18-10-2012 дата публикации

Compositions for the treatment of cns-related conditions

Номер: US20120264782A1
Принадлежит: Adamas Pharmaceuticals Inc

The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

Подробнее
25-10-2012 дата публикации

Lipid depot formulations

Номер: US20120269772A1
Принадлежит: CAMURUS AB

The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Подробнее
01-11-2012 дата публикации

Sustained release latanoprost implant

Номер: US20120276186A1
Принадлежит: Allergan Inc

The present invention provides a sustained release, biodegradable intraocular latanoprost implant for reducing elevated intraocular pressure in an individual in need thereof. The implant can be configured as a film (e.g., a rolled film) or extruded filament, either of which can be inserted into the eye of the individual to provide for extended release of latanoprost for several days. Upon insertion into the eye, a rolled film may unroll to provide a film having a high surface area to volume ratio for drug diffusion.

Подробнее
08-11-2012 дата публикации

Percutaneous absorption preparation comprising anti-dementia drug

Номер: US20120282303A1
Автор: Takeshi Ito
Принадлежит: Individual

The present invention relates to a percutaneous absorption preparation that is lower skin irritation and enables efficient transdermal administration of an anti-dementia drug. More specifically, the present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, a polymer compound having an amino group, a polyvalent carboxylate ester, a fatty acid alkyl ester, a styrenic polymer compound, and a tackifier resin.

Подробнее
08-11-2012 дата публикации

Percutaneous absorption preparation comprising anti-dementia drug

Номер: US20120283670A1
Автор: Takeshi Ito
Принадлежит: Individual

The present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, which is lower skin irritation. More specifically, the present invention relates to a percutaneous absorption preparation comprising a drug-containing layer comprising an anti-dementia drug, a polymer compound having an amino group, a polyhydric alcohol fatty acid ester, a polyhydric alcohol, a polyvalent carboxylate ester, and a styrenic polymer compound, wherein the content of the anti-dementia drug is 0.5-20 mass % of the drug-containing layer.

Подробнее
15-11-2012 дата публикации

Methods for the Treatment of CNS-Related Conditions

Номер: US20120288560A1
Принадлежит: Adamas Pharmaceuticals Inc

The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.

Подробнее
06-12-2012 дата публикации

Piroxicam-Containing Transdermally Absorbable Preparation

Номер: US20120309749A1
Принадлежит: Teikoku Seiyaku Co Ltd

An adhesive patch is provided in which piroxicam is formulated as a non-steroidal anti-inflammatory analgesic. In particular, provided is a piroxicam-containing transdermally absorbable adhesive patch in which an absorption promoter to piroxicam is formulated to achieve high anti-inflammatory and analgesic effects without inhibiting releasing of these drugs. The piroxicam-containing transdermally absorbable adhesive patch contains piroxicam as a medicinal component and oxybuprocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In the piroxicam-containing transdermally absorbable adhesive patch, the content of piroxicam is from 0.1% to 5% by weight to the total weight of a drug-containing plaster and the content of oxybuprocaine or the pharmaceutically acceptable salt thereof is from 1% to 30% by weight to the total weight of the drug-containing plaster.

Подробнее
13-12-2012 дата публикации

Tape Preparation

Номер: US20120316519A1
Автор: Masanori Uematsu
Принадлежит: Teikoku Seiyaku Co Ltd

A tape preparation is provided which does not use a backing such as a plastic film, knit or a woven fabric, or a nonwoven fabric, has very high conformability to skin, and is easy to use at the time of application. There is provided a tape preparation 1 that is produced by laminating a drug-containing adhesive layer 4 on the printed ink layer 3 side of a cover film 2 with printing thereon and covering the drug-containing adhesive layer with a release film 5. In this tape preparation, the adhesive strength between the cover film and the printed ink layer is higher than the adhesive strength between the drug-containing adhesive layer and the release film, and the adhesive strength between the printed ink layer and the drug-containing adhesive layer is higher than the adhesive strength between the cover film and the printed ink layer.

Подробнее
03-01-2013 дата публикации

Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same

Номер: US20130004586A1
Принадлежит: Individual

Compositions, solid polymeric compositions, and/or articles of manufacture are provided that can include a polymer matrix having a plurality of ion-exchange particles distributed therein. Products by process are provided that can include prior to solidifying the polymeric precursors, blending the precursors with ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition product. Solid polymeric composition production methods are also provided that can include providing a plurality of ion-exchange particles, prior to solidifying the polymeric precursors, blending the precursors with the ion-exchange particles to form a mixture, and solidifying the mixture to form a solid polymeric composition. Article of manufacture production methods are provided that can include incorporating a solid polymeric composition into an article of manufacture, the solid polymeric composition including a polymer matrix and a plurality of ion-exchange particles distributed therein.

Подробнее
03-01-2013 дата публикации

Ketoprofen-Containing Aqueous Adhesive Skin Patch

Номер: US20130005817A1
Автор: Kazuha Tani
Принадлежит: Teikoku Seiyaku Co Ltd

Provided is a water-based patch that contains ketoprofen as an active ingredient, provides high transdermal absorbability of the ketoprofen, and has high safety and high storage stability. The water-based patch contains the ketoprofen, an amine, and polyethylene glycol. In the water-based patch, the added amount of the ketoprofen in a paste is 0.1 to 5% by weight, the added amount of the amine in the paste is 0.5 to 10% by weight, and the added amount of the polyethylene glycol in the paste is 5 to 30% by weight. Particularly, in the water-based patch, diisopropanolamine is used as the amine.

Подробнее
10-01-2013 дата публикации

Melt extruded nicotine thin strips

Номер: US20130011462A1
Принадлежит: NOVARTIS AG

A thin strip for oral ingestion is between 0.05 millimeters and 2.00 millimeters thick. It includes 10 to 80% by weight of polyethylene oxide having a molecular weight of from 70,000 to 300,000 daltons. It further includes 5 to 50% by weight of a sugar alcohol having a melting point in excess of 75 C and 5 to 30% by weight of polyethylene glycol having a molecular weight of from 200 to 1,000 daltons. Lastly it includes 1 to 30% by weight of a carboxy vinyl polymer cross linked with an allyl ether of pentaerythritol, and 1 to 10% by weight of an organic acid addition salt of nicotine.

Подробнее
17-01-2013 дата публикации

Orally administered agent and an orally administered agent/supporting substrate complex

Номер: US20130017235A1
Автор: Eiji Nogami
Принадлежит: Lintec Corp

With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent 1 b having one drug-containing layer 11 and two water-swellable gel-forming layers 12, the water-swellable gel-forming layers 12 are provided, either directly or via intermediate layers, on the both faces of the drug-containing layer 11.

Подробнее
31-01-2013 дата публикации

Transdermal Delivery Systems for Sufentanil

Номер: US20130028953A1
Автор: Felix Theeuwes, Su Ii Yum
Принадлежит: Durect Corp

Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.

Подробнее
14-02-2013 дата публикации

Oral dosage forms

Номер: US20130039967A1
Автор: Nicole Ouis, Stephan Meyer
Принадлежит: NOVARTIS AG

The invention relates to specific three layer dosage forms for oral administration of pharmaceutical active substances.

Подробнее
21-02-2013 дата публикации

Steroid hormone delivery systems and methods of preparing the same

Номер: US20130045271A1
Принадлежит: MONOSOL RX LLC

The present invention is directed to steroid hormone delivery systems and methods of preparing the same. In particular, the steroid hormone delivery systems provided include a primary construct having one or more hydrophobic steroid hormone esters in the form of a liposome, a lipid particle, a micelle, an emulsion or a niosome which is then formulated into a secondary construct for administration. Exemplary secondary constructs include a film for sublingual or buccal administration.

Подробнее
14-03-2013 дата публикации

Drug-containing implants and methods of use thereof

Номер: US20130064773A1
Автор: Karen Winey, Steven Siegel
Принадлежит: University of Pennsylvania Penn

The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.

Подробнее
21-03-2013 дата публикации

CELL CONSTRUCT FOR CELL TRANSPLANTATION AND CELL AGGREGATE FOR CELL TRANSPLANTATION

Номер: US20130071441A1
Принадлежит: FUJIFILM Corporation

An object of the present invention is to provide a cell construct for cell transplantation capable of having a thickness suitable for cell transplantation, preventing the necrosis of transplanted cells, and forming blood vessels in the transplantation site after transplantation. The present invention provides a cell construct for cell transplantation which comprises polymer blocks having biocompatibility and cells of at least one type, wherein the plural polymer blocks are arranged in spaces between the plural cells. 1. A cell construct for cell transplantation which comprises polymer blocks having biocompatibility and cells of at least one type , wherein the plural polymer blocks are arranged in spaces between the plural cells.2. The cell construct for cell transplantation according to claim 1 , wherein the polymer having biocompatibility is polypeptide claim 1 , polylactic acid claim 1 , polyglycolic acid claim 1 , PLGA claim 1 , hyaluronic acid claim 1 , glycosaminoglycan claim 1 , proteoglycan claim 1 , chondroitin claim 1 , cellulose claim 1 , agarose claim 1 , carboxymethylcellulose claim 1 , chitin claim 1 , or chitosan.3. The cell construct for cell transplantation according to claim 1 , wherein the polymer having biocompatibility is a recombinant peptide.4. The cell construct for cell transplantation according to claim 1 , wherein the polymer having biocompatibility has two or more cell adhesion signals in a molecule.5. The cell construct for cell transplantation according to claim 3 , wherein the recombinant peptide is represented by the formula:{'br': None, 'sub': n', 'm, 'A-[(Gly-X-Y)]-B'}wherein A represents any amino acid or amino acid sequence; B represents any amino acid or amino acid sequence; each X of total n independently represents any amino acid; each Y of total n independently represents any amino acid; n represents an integer of 3 to 100; m represents an integer of 2 to 10; and each Gly-X-Y of total n may be the same as or different from each ...

Подробнее
21-03-2013 дата публикации

Wound Healing Device

Номер: US20130071457A1
Принадлежит: STEMNION, INC.

The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix. 111.-. (canceled)12. A skin wound healing device for topical administration comprising a cloth which is embedded with a skin wound healing composition , wherein the skin wound healing composition consists of protein factors selected from the group consisting of physiologic levels of VEGF , Angiogenin , PDGF , TGFβ2 , TIMP-1 and TIMP-2 that are dissolved in a carrier , wherein the physiologic levels are ˜5-16 ng/mL for VEGF , ˜3.5-4.5 ng/mL for Angiogenin , ˜100-165 pg/mL for PDGF , ˜2.5-2.7 ng/mL for TGFβ2 , ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2.13. The skin wound healing device of wherein the cloth has the property of hemostatic activity and/or anti-infectious agent and/or antibacterial activity.14. The skin wound healing device of wherein the cloth is made of a natural claim 12 , plant-derived fiber.15. The skin wound healing device of wherein the plant-derived fiber has a rough surface.16. The skin wound healing device of which has been irradiated to achieve sterility.17. The skin wound healing device of which is contained in a sterile package.18. The skin wound healing device of wherein the cloth is made of a natural claim 12 , plant-derived fiber and another fiber or material selected from the group consisting of glass claim 12 , Teflon® claim 12 , Gor-Tex® claim 12 , hair and feathers.19. The skin wound healing device of wherein the carrier is selected from the group consisting of normal saline claim 12 , PBS claim 12 , lactated Ringer's solution and cell culture medium. This application is a divisional application of U.S. application Ser. No. 13/134,881, filed Jun. 20, 20011 and claims priority under 35 USC §119(e) of U.S. Provisional Application No. 61/398,167, filed Jun. 22, 2010, and U.S. Provisional Application No. 61/398,751, filed Jun. 30, 2010, the ...

Подробнее
21-03-2013 дата публикации

IMPLANTS FOR POSTOPERATIVE PAIN

Номер: US20130071463A1
Принадлежит:

Medical implants and methods useful in treating postoperative pain are described. The implants comprise one or more electrospun drug-loaded fibers, which fibers comprise a drug useful in the treatment of pain. The implants are implanted at sites of interest including joint capsules, bones, and subcutaneous spaces, and are secured with tissue flaps or fasteners. 1. A method of treating a patient , comprising:disposing, within a patient, an implant comprising a core-sheath fiber having a core comprising an analgesic and an outer diameter of no more than about 20 microns, wherein the core of the core-sheath fiber contains a first polymer and the sheath of the core-sheath fiber contains a second polymer different than the first polymer.2. The method of claim 1 , wherein the implant is one of a rope and a yarn claim 1 , and disposing the implant within the tissue of a patient includes bending the implant to fit inside a space in or near the tissue of the patient.3. The method of claim 1 , wherein the implant is secured to a tissue of the patient by at least one of a tissue flap claim 1 , a suture claim 1 , a knot and a tissue fastener.4. The method of claim 1 , wherein the implant includes a coating that is erodible and/or biodegradable.5. The method of claim 1 , wherein the core of the core-sheath fiber contains a first polymer and the sheath of the core-sheath fiber contains a second polymer different than the first polymer.6. A method of treating a patient claim 1 , comprising:disposing an implant within the patient to thereby increase a concentration of an analgesic in a tissue of the patient above a first threshold level for a period of at least one week, the implant including at least one core-sheath fiber having a core comprising the analgesic agent,wherein a concentration of the analgesic within a plasma of the patient is not increased above a second threshold level for more than one day.7. The method of claim 6 , wherein the implant is disposed into a joint ...

Подробнее
21-03-2013 дата публикации

Transdermal compositions comprising an active agent layer and an active agent conversion layer

Номер: US20130072884A1
Автор: Jianye Wen, Richard Hamlin
Принадлежит: Teikoku Pharma USA Inc

Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.

Подробнее
28-03-2013 дата публикации

Transdermal Patches Having Ionized Beam Crosslinked Polymers and Improved Release Characteristics

Номер: US20130078299A1
Принадлежит: Alliqua, Inc.

Crosslinked hydrogel-based transdermal pharmaceutical formulations. The hydrogel transdermal formulations. Transdermal patches are useful for administering a variety of drugs to patients. The transdermal patches here employ crosslinked-hydrogels generated through irradiation, thus eliminating any residual effects associated with chemical- or UV-based crosslinking procedures. The transdermal patches may be formed from a variety of high-molecular weight polymeric compounds and include substantial levels of water to improve skin tolerance by the patient. The transdermal patches may also include transcutol as a solvent for the drug, which has been found to increase the effectiveness of drug delivery. The present disclosure also provides for methods of loading a drug into a transdermal formulation after the crosslinking of the hydrogel, thus improving stability and bioavailability through avoiding exposure of the drug to the radiation used in the crosslinking procedure. The transdermal patches here are particularly effective in delivering lidocaine to patients in need thereof. 1. A transdermal formulation for administering a medicament to a patient in need thereof , comprising:a hydrogel, said hydrogel comprising a polymer-water mixture and transcutol, wherein said hydrogel is generated by exposing said polymer-water mixture to ionizing radiation; andsaid medicament dispersed in said hydrogel.2. The transdermal formulation of claim 1 , wherein said medicament is lidocaine.3. The transdermal formulation of claim 2 , wherein said transdermal formulation delivers two to four times more lidocaine to said patient over a twelve-hour period than LIDODERM®.4. The transdermal formulation of claim 1 , wherein said polymer is selected from the group consisting of polyethylene oxide claim 1 , polyvinylpyrrolidone claim 1 , polyethylene glycol claim 1 , and mixtures thereof.5. The transdermal formulation of claim 1 , wherein said polymer-water mixture comprises from about 3% to about ...

Подробнее
11-04-2013 дата публикации

METHOD OF PREVENTIVE ON-DEMAND HORMONAL CONTRACEPTION

Номер: US20130089574A1
Принадлежит: Bayer Pharma AG

The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse. 1. A method of hormonal female controlled on-demand contraception , characterized in that a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse.2. The method as claimed in claim 1 , characterized in that the pharmaceutical preparation is administered at the latest just prior to the first anticipated intercourse.3. The method as claimed in claim 2 , characterized in that the pharmaceutical preparation is administered no earlier than 12 hours prior to intercourse.4. The method as claimed in claim 1 , characterized in that the progestogen administered is selected from the group of compounds:desogestrel,etonorgestrel,gestodene,levonorgestrel ortrimegestone.5. The method as claimed in claim 4 , characterized in that the progestogen is released daily in an amount which results in endogenous progestogen levels which are equivalent in effect to endogenous gestodene levels developing after daily transdermal administration of 50 to 100 μg of gestodene.6. The method as claimed in claim 5 , characterized in that 50 to 100 μg of gestodene are administered daily.7. The method as claimed in claim 1 , characterized in that an estrogen is administered in addition.8. The method as claimed in claim 7 , characterized in that the estrogen administered is ethinylestradiol.9. The method as claimed in claim 8 , characterized in that the ethinylestradiol is administered in an amount which brings about a daily release of 10 to 30 μg of ethinylestradiol.10. A pharmaceutical preparation for use in any of the aforementioned methods as claimed in .11. A transdermal patch comprising exclusively one claim 1 , or more ...

Подробнее
18-04-2013 дата публикации

CUSTOMIZED COMPOSITIONS AND USES THEREOF

Номер: US20130095167A1
Автор: WARNKE PATRICK
Принадлежит: BOND UNIVERSITY LTD

The present invention relates to a customized composition comprising three-dimensional (3D) nanofiber webbing. The present invention further relates to the process of producing the composition comprising 3D nanofiber webbing and uses thereof such as treatment of age-related macular degeneration or regeneration/repair of tissue. 1. A composition to regenerate or repair tissue , wherein the composition comprises three-dimensional (3D) nanofiber webbing and at least one agent , wherein the webbing comprises at least a first layer and a second layer wherein the first and second layers are distinct from each other , and wherein the thickness of the composition corresponds to the thickness of the tissue when healthy , wherein the first and second layers of the webbing correspond to a first layer and a second layer of the tissue.2. The composition of claim 1 , wherein the first layer and the second layer of the composition correspond to the first layer and the second layer of the tissue by mimicking extracellular matrix or a layer of cells.3. The composition of claim 1 , wherein a layer of the composition which corresponds to a layer of cells in the tissue is seeded with one or more cells.4. The composition of claim 3 , wherein the seeded cells are the same cell type as the cells in the tissue layer.5. The composition of claim 3 , wherein the seeded cells differ to the cell type of the cells in the tissue layer but allowed to differentiate into the same cell type through cultivation.6. The composition of claim 3 , wherein the seeded cells are stem cells.7. The composition of claim 6 , wherein the stem cells are human.8. The composition of claim 1 , wherein the composition comprises three claim 1 , four or more layers.9. The composition of claim 1 , wherein the composition is amendable and is contoured to the shape of the tissue.10. The composition of claim 8 , wherein each of the first claim 8 , second claim 8 , third claim 8 , fourth or more layers of the webbing consists ...

Подробнее
18-04-2013 дата публикации

Method of forming hemostatic products

Номер: US20130096479A1
Принадлежит: St Teresa Medical Inc

A hemostatic product having a plurality of hemostatic layers. Each of the hemostatic layers includes a dextran support and at least one hemostatic agent, which is selected from the group consisting of thrombin and fibrinogen. The hemostatic layers are arranged in a stacked configuration.

Подробнее
25-04-2013 дата публикации

CELL SHEET FOR MYOCARDIAL REGENERATION, METHOD OF PRODUCING THE SAME, AND METHOD OF USING THE SAME

Номер: US20130101659A1
Принадлежит:

Provided are a cell sheet and a three-dimensional structure thereof that include at least mesenchymal stem cells and myoblasts isolated from a cell culture support and that are to be applied to heart disease. Use of the cell sheet and the three-dimensional structure thereof including mesenchymal stem cells and myoblasts can notably improve cardiac functions compared with a conventional technology, i.e., use of cell sheets composed of myoblasts only or mesenchymal stem cells only. Furthermore, the cell sheet itself has high strength, and the transplantation procedure is also improved. 1. A cell sheet and a three-dimensional structure thereof to be applied to heart disease , comprising at least mesenchymal stem cells and myoblasts isolated from a cell culture support.2. The cell sheet and the three-dimensional structure thereof according to claim 1 , wherein the cell sheet comprises a mixture of mesenchymal stem cells and myoblasts.3. The cell sheet and the three-dimensional structure thereof according to claim 2 , wherein the mesenchymal stem cells are contained in an amount of 5 to 95%.4. The cell sheet and the three-dimensional structure thereof according to any one of to claim 2 , wherein the three-dimensional structure is a stack of a plurality of layers of the cell sheet.5. The cell sheet and the three-dimensional structure thereof according to claim 4 , wherein the three-dimensional structure is a stack of a cell sheet comprising myoblasts and a cell sheet comprising mesenchymal stem cells.6. The cell sheet and the three-dimensional structure thereof according to any one of to claim 4 , having at least one function selected from the group consisting of fibrosis inhibition claim 4 , angiogenesis claim 4 , and apoptosis inhibition.7. The cell sheet and the three-dimensional structure thereof according to any one of to claim 4 , wherein the mesenchymal stem cells are derived from adipose tissue.8. The cell sheet and the three-dimensional structure thereof ...

Подробнее
25-04-2013 дата публикации

TRANSDERMAL DELIVERY PATCH

Номер: US20130101660A1
Принадлежит: PHOSPHAGENICS LIMITED

A composition suitable for use in a transdermal delivery patch for administration of an opioid, the composition comprising a phosphate compound of tocopherol and a polymer carrier. 1. A transdermal delivery patch comprising:(i) a backing layer, and a) a composition comprising a mixture of a mono-tocopheryl phosphate compound and a di-tocopheryl phosphate compound, and a polymer carrier, wherein the polymer carrier is present in an amount of about 20% w/w to about 90% w/w of the total weight of the composition, and', 'b) an opioid., '(ii) a matrix layer comprising2. The transdermal delivery patch of claim 1 , wherein mono-tocopheryl phosphate compound is selected from the group consisting of mono-(tocopheryl) phosphate claim 1 , mono-(tocopheryl) phosphate monosodium salt claim 1 , mono-(tocopheryl) phosphate disodium salt claim 1 , mono-(tocopheryl) phosphate monopotassium salt and mono-(tocopheryl) phosphate dipotassium salt claim 1 , and the di-tocopheryl phosphate compound is selected from the group consisting of di-(tocopheryl) phosphate claim 1 , di-(tocopheryl) phosphate monosodium salt and di-(tocopheryl) phosphate monopotassium salt.3. The transdermal delivery patch of claim 1 , wherein the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound is present in an amount within the range of about 0.01% w/w to about 10% w/w of the total concentration of the composition.4. The transdermal delivery patch of claim 1 , wherein the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound is present in an amount within the range of about 0.1% w/w to about 5% w/w of the total concentration of the composition.5. The transdermal delivery patch of claim 1 , wherein the mixture of the mono-tocopheryl phosphate compound and the di-tocopheryl phosphate compound is present in an amount within the range of about 0.05% w/w to about 3% w/w of the total concentration of the composition.6. The transdermal ...

Подробнее
02-05-2013 дата публикации

WOUND CARE PRODUCT COMPRISING A CATHELICIDIN POLYPEPTIDE

Номер: US20130108682A1
Автор: WESTRIN Bengt
Принадлежит: LIPOPEPTIDE AB

The present invention provides a wound care product comprising a wound care material and a polypeptide having wound care properties. In one embodiment, the wound care material comprises or consists of alginates, amorphous hydrogels, sheet hydrogels, hydrofibres, foams and mixtures thereof. In a further embodiment, the polypeptide having wound care properties is a cathelicidin, such as LL-37. The invention further provides methods of treatment of wounds using the products of the invention. 1. A wound care product comprising a wound care material and a polypeptide having wound healing properties , wherein the polypeptide having wound healing properties is a cathelicidin , or a fragment , variant or fusion thereof which retains , at least in part , the wound healing activity of said cathelicidin.2. The wound care product according to claim 1 , wherein the cathelicidin is selected from the group consisting of human cationic antimicrobial protein (hCAP18) claim 1 , PR39 claim 1 , prophenin and indolicidin.3. The wound care product according to claim 1 , wherein the polypeptide having would healing properties is LL-37.4. The wound care product according to claim 1 , wherein the wound care material is selected from the group consisting of alginates claim 1 , amorphous hydrogels claim 1 , sheet hydrogels claim 1 , hydrofibres claim 1 , foams claim 1 , hydrocolloids claim 1 , collagen-based materials claim 1 , hyaluronic acid based materials claim 1 , dextranomers claim 1 , dextrinomer/cadexomer claim 1 , oxidised regenerated cellulose and mixtures thereof.5. The wound care product according to claim 1 , wherein the wound care material comprises or consists of an amorphous hydrogel.6. The wound care product according to claim 1 , wherein the hydrogel comprises one or more hydrogel-forming polymers selected from the group consisting of synthetic polymers claim 1 , such as polyvinylalcohol claim 1 , polyvinylpyrolidone claim 1 , polyacrylic acid claim 1 , polyethylene glycol ...

Подробнее
02-05-2013 дата публикации

COMPOSITIONS AND METHODS FOR TREATING PARTIAL AND FULL THICKNESS WOUNDS AND INJURIES

Номер: US20130108683A1
Автор: Lynch Samuel Eugene
Принадлежит: BIOMIMETIC THERAPEUTICS, INC.

The present invention provides compositions and methods for treating deep partial thickness or full thickness wounds or injuries. The present invention also provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such partial thickness or full thickness wounds or injuries, as well as promoting vascularization and angiogenesis in regenerating and/or supportive tissue at such sites. 1. A method of treating , promoting healing at and/or promoting vascularization of a wound or injury site in a subject in need thereof , the method comprising:a) applying a composition comprising a biocompatible matrix and an effective amount of platelet-derived growth factor (PDGF) disposed therein to the site.2. The method according to claim 1 , wherein the wound or injury site comprises impairment or damage to at least one tissue selected from the group consisting of bone claim 1 , periosteum claim 1 , tendon claim 1 , muscle tissue claim 1 , fascia claim 1 , nerve tissue claim 1 , a visceral organ claim 1 , subcutaneous tissue claim 1 , integument claim 1 , and combinations thereof.3. The method according to claim 1 , wherein the wound or injury site is a deep partial or full thickness wound or injury site.4. The method of claim 1 , wherein the method further comprises debriding at least a portion of a site of impaired claim 1 , damaged claim 1 , or necrotic tissue prior to performing step (a).5. The method of claim 1 , wherein the method further comprises decorticating at least a portion of impaired or damaged bone at the site prior to performing step (a).6. The method of claim 1 , wherein at least one intramarrow bone penetration is performed at the site.7. The method according to claim 1 , wherein the injury is caused by at least one of the following: a blunt force trauma; a penetrating trauma; a gunshot wound; a microbial infection; a necrotizing infection; a bacterial infection; a fungal infection; hypothermia; frostbite; ...

Подробнее
16-05-2013 дата публикации

NANOFIBER LAMINATE SHEET

Номер: US20130122069A1
Принадлежит: KAO CORPORATION

A nanofiber laminate sheet including a nano fiber layer containing a cosmetic component or a medicinal component and a water soluble base layer located on at least one side of the nano fiber layer. The water soluble base layer is less water-soluble than the nanofiber layer. The water soluble base layer is preferably constructed of nano fiber portions mingled with filmy portions. The water soluble base layer is preferably a layer of nanofibers in which nanofibers cohere to each other to form the filmy portions at their intersections. 16-. (canceled)7. A nanofiber laminate sheet comprising a nanofiber layer containing a cosmetic component or a medicinal component , and a water soluble base layer located on at least one side of the nanofiber layer , the water soluble base layer being less water-soluble than the nanofiber layer.8. The nanofiber laminate sheet according to claim 7 , wherein the nanofiber comprises a water soluble polymer.9. The nanofiber laminate sheet according to claim 7 , wherein the water soluble base layer and the nanofiber comprise the same material claim 7 ,the water soluble base layer has a smaller specific surface area than the nanofiber layer, andthe water soluble base layer comprises a poreless film, a porous film, or a mesh.10. The nanofiber laminate sheet according to claim 7 , wherein the water soluble base layer is a film prepared from a polysaccharide material claim 7 , polyvinyl alcohol claim 7 , agar claim 7 , or carrageenan.11. The nanofiber laminate sheet according to claim 7 , wherein the content of the cosmetic component or the medicinal component in the nanofiber is in the range of from 0.01% to 70% by mass.12. The nanofiber laminate sheet according to claim 7 , wherein the water soluble base layer is constructed of a nanofiber portion and a filmy portion claim 7 , the nanofiber portion and the filmy portion being mingled with each other.13. The nanofiber laminate sheet according to claim 7 , wherein the water soluble base layer is ...

Подробнее
16-05-2013 дата публикации

MUCOSAL FORMULATION

Номер: US20130122124A1
Принадлежит: IZUN PHARMACEUTICALS CORPORATION

Provided, among other things, is a method of treating or ameliorating an indication of mucosal or adjacent tissue comprising periodically applying to mucosa at or adjacent to disease affected tissue a rinse comprising: an effective amount of appropriate composition of herbal bioactive comprising active(s) of one or more of or ; an antimicrobially effective amount of a quaternary ammonium surfactant; and optionally a polymer or mixture of polymers effective to coat said tissue and entrap said extract(s). 1. A method of treating or ameliorating an indication of anal or vaginal mucosal or adjacent tissue comprising periodically applying to anal or vaginal mucosa at or adjacent to disease affected tissue a formulation comprising{'i': Sambucus nigra, Centella asiatica', 'Echinacea purpurea', 'Sambucus nigra', 'Centella asiatica, 'an antiinflammatory effective amount of herbal extracts including and defining a weight amount of plant extract solids in the formulation, wherein extract is more than 50% to 90% by weight of the plant extract solids and is 1% to less than 50% by weight of the plant extract solids,'}a plasticizer in an amount from 10 to 45% by weight of the formulation, andan antimicrobially effective amount of a surfactant that is a 1-alkylpyridinium salt, where alkyl is C8-C36, the surfactant present in an amount from 0.01 to 2% of the formulation by weight.an antimicrobially effective amount of a quaternary ammonium surfactant.2. The method of claim 1 , wherein the formulation comprises film-forming polymer(s).3. The method of claim 2 , wherein the film-forming polymer(s) provide a mucoadhesive film.4. The method of claim 1 , wherein the 1-alkylpyridinium salt is a cetylpyridinium salt.5Sambucus nigra. The method of claim 4 , wherein extract comprises 60 to 99% by weight of plant extract solids in the formulation.6Centella asiatica. The method of claim 5 , wherein extract comprises 1 to 20% by weight of plant extract solids in the formulation.7Echinacea ...

Подробнее
23-05-2013 дата публикации

COLLAGEN-BASED IMPLANTS FOR SUSTAINED DELIVERY OF DRUGS

Номер: US20130129807A1
Принадлежит:

The disclosure provides collagen-based constructs for use in drug delivery. 1. A collagen-based , ultraviolet radiation crosslinked , film , wafer , or membrane construct comprising at least one layer of chemically derivatized collagen and an amount of an ophthalmic , otic , or nasal drug that has low water or aqueous solubility , wherein the amount of the drug is sufficient to provide a therapeutically effective amount of drug per day over a period of about six months , and further wherein the construct has been exposed to ultraviolet radiation crosslinking for a period of 17 to 19 minutes in a low oxygen environment.2. The collagen-based film claim 1 , wafer claim 1 , or membrane of claim 1 , wherein the drug present in the film claim 1 , wafer claim 1 , or membrane is resistant to removal by a 1 day treatment in an aqueous buffer.3. The collagen-based film claim 2 , wafer claim 2 , or membrane of claim 2 , wherein the drug present in the film claim 2 , wafer claim 2 , or membrane is resistant to removal by a 7 day treatment in an aqueous buffer.4. The film claim 2 , wafer claim 2 , or membrane of any one of to claim 2 , further comprising a barrier layer of collagen derivatized by an acylation agent.5. A collagen-based claim 2 , ultraviolet radiation crosslinked claim 2 , film claim 2 , wafer claim 2 , or membrane delivery system comprising at least one layer of glutaric anhydride-derivatized collagen and at least about 150 μg of Latanoprost claim 2 , wherein the film claim 2 , wafer claim 2 , or membrane has been crosslinked with ultraviolet radiation for from 17 to 19 minutes.6. The collagen-based film claim 5 , wafer claim 5 , or membrane of claim 5 , wherein the film claim 5 , wafer claim 5 , or membrane provides sustained and/or controlled release of about 1.5 μg Latanoprost per day for at least about 6 months but for less than one year.7. The film claim 5 , wafer claim 5 , or membrane delivery system of claim 5 , wherein the film claim 5 , wafer claim 5 , ...

Подробнее
23-05-2013 дата публикации

Natural combination hormone replacement formulations and therapies

Номер: US20130129818A1
Принадлежит: TherapeuticsMD Inc

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Подробнее
30-05-2013 дата публикации

METHODS FOR DELIVERY OF MEDICATION USING DISSOLVABLE DEVICES

Номер: US20130136784A1
Автор: Staab Robert J.
Принадлежит:

A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora. 1. A method for the delivery of an agent material into an internal body cavity for the delivery of medicines , contraceptives and for pH controlling , which comprises introducing a device characterized by improved heat and humidity stability into said cavity , said device comprising at least one dissolvable element formed from a member selected from the group consisting of polyvinyl alcohol , polyethylene oxide , hydroxypropylmethyl cellulose and mixtures thereof , and wherein said device is a tampon comprising a non-woven fibrous structure selected from the group consisting of non-woven fabrics and masses of randomly intermingled fibers and at least one agent material which is a member selected from the group consisting of ascorbic acid , spermicide , anti-infectives , anti-inflammatories , estrogenic steroids , progestational agents , prostaglandins , coronary vasodilators , antitussives , antihistamines , contraceptives and anesthetics.2. A method according to wherein said device is a non-woven fabric formed from fibers.3. A method according to wherein said device is a fibrous structure comprising a mass of randomly intermingled fibers.4. A method according to wherein said body cavity comprises a member selected from the mouth claim 1 , vagina claim 1 , rectum claim 1 , ear canal and eye.5. A method according to wherein said device contains as agent material a spermicide for contraceptive use.6. A method according to wherein said agent material is ascorbic acid for pH regulation.7. A method according ...

Подробнее
06-06-2013 дата публикации

NANOFIBER LAMINATE SHEET

Номер: US20130142852A1
Принадлежит: KAO CORPORATION

A nanofiber laminate sheet including a layer of a nanofiber of a water insoluble polymer and a layer of a water soluble polymer containing a cosmetic component or a medicinal component. The nanofiber is preferably colored. The layer of a water soluble polymer is preferably a layer of a nanofiber of the water soluble polymer containing the cosmetic component or the medicinal component. The nanofiber laminate sheet is suited for use as a cosmetic sheet for makeup. 114-. (canceled)15. A nanofiber laminate sheet comprising a layer of a nanofiber of a water insoluble polymer , and a layer of a water soluble polymer containing a cosmetic component or a medicinal component ,the layer of a water soluble polymer comprising a layer of a nanofiber.16. The nanofiber laminate sheet according to claim 15 , wherein the layer of a water insoluble nanofiber comprises a nanofiber of a water insoluble polymer containing a coloring pigment claim 15 , andthe nanofiber laminate sheet is for use as a cosmetic sheet for makeup.17. The nanofiber laminate sheet according to claim 16 , having an outer color with a hue of 5.0 R to 9.8 YR claim 16 , a value of 5.0 to 8.0 claim 16 , and a chroma of 2.5 to 6.0 in the Munsell color system.18. The nanofiber laminate sheet according to claim 15 , wherein the layer of a water insoluble nanofiber contains a composite nanofiber comprising a nanofiber and a particle fixed to the nanofiber claim 15 , andthe particle has a particle size greater than the thickness of the nanofiber and is covered with a material constituting the nanofiber.19. The nanofiber laminate sheet according to claim 18 , wherein the nanofiber of the composite nanofiber has a thickness of 10 to 3000 nm claim 18 , and the particle has a particle size of 1 to 100 μm.20. The nanofiber laminate sheet according to claim 18 , wherein the particle is a platy particle.21. The nanofiber laminate sheet according to claim 15 , wherein a base sheet is provided on one side of the nanofiber ...

Подробнее
06-06-2013 дата публикации

MATERIAL COMPOSITIONS WHICH COMPRISE ADULT STEM CELLS OBTAINED FROM EXOCRINE GLANDULAR TISSUE, IN PARTICULAR FOR USE IN REGENERATIVE MEDICINE

Номер: US20130142860A1

The invention relates to material compositions comprising adult stem cells obtained from exocrine gland tissue and a supporting matrix having the shape of a thread structure and/or of a net. The supporting matrix preferably consists of a plastic material which is physiologically acceptable and degradable in the body. The material compositions of the invention are in particular suited for use in regenerative medicine, e.g. for regeneration of injured or damaged myocard tissue. 1. A bidirectionally transformable stem cell patch (BTS) , comprisinga) adult stem cells that have been isolated from exocrine gland tissue of an organism;b) a porous matrix in the shape of a thread structure or a net for receiving the cells; andc) a broad supporting surface of the BTS for placement on a broad myocardial wound surface.2. The stem cell patch according to claim 1 , wherein the stem cells are human stem cells.3. The stem cell patch according to claim 1 , wherein all the constituents are degradable in the body.4. The stem cell patch according to claim 1 , further comprising cells entirely or partially differentiated out to heart muscle cells. This application is a divisional of U.S. patent application Ser. No. 12/670,587, filed Jun. 29, 2010, which is a National Phase Application of PCT International Application No. PCT/EP2008/005680, International Filing Date Jul. 11, 2008, claiming priority from German Patent Application No. DE 10 2007 034 679.6, filed Jul. 25, 2007, all of which are incorporated by reference herein.Heart failure is one of the main causes of death in industrialised countries and is a result of the inability of mature heart muscle cells (cardiomyocytes) to divide and replace damaged heart muscle. Since the therapeutic use of embryonic cardiomyocytes is prohibited in most countries, adult human stem cells could represent an alternative for regenerative medicine. Adult stem cells of differing origin have previously been injected intramyocardially in order to be ...

Подробнее
13-06-2013 дата публикации

Pharmaceutical composition comprising a curcumin derivative

Номер: US20130150628A1
Автор: Thomas M. DiMauro
Принадлежит: Individual

The present invention is directed to a pharmaceutical composition comprising:

Подробнее
20-06-2013 дата публикации

TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

Номер: US20130156815A1
Автор: Mantelle Juan
Принадлежит:

Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described. 1. A monolithic transdermal drug delivery system for estradiol , comprising a single polymer matrix layer defining an active surface area and comprising a polymer matrix comprising estradiol as the only drug , wherein the polymer matrix layer includes greater than 0.156 mg/cmestradiol and achieves an estradiol flux that is greater than 0.01 mg/cm/day , based on the active surface area.2. The transdermal drug delivery system of claim 1 , wherein the polymer matrix comprises a polymer blend comprising an acrylic adhesive claim 1 , a silicone adhesive claim 1 , and soluble PVP.3. The transdermal drug delivery system of claim 1 , wherein the polymer matrix comprises about 2-25% by weight acrylic adhesive claim 1 , about 45-70% by weight silicone adhesive claim 1 , about 2-25% by weight soluble PVP claim 1 , about 5-15% penetration enhancer claim 1 , and about 0.1-10% by weight estradiol claim 1 , all based on the total dry weight of the polymer matrix.4. The transdermal drug delivery system of claim 3 , wherein the penetration enhancer comprises oleyl alchol.5. The transdermal drug delivery system of claim 3 , wherein the penetration enhancer comprises dipropylene glycol.6. The transdermal drug delivery system of claim 3 , wherein the penetration enhancer comprises oleyl alcohol and dipropylene glycol.7. The transdermal drug delivery system of claim 3 , wherein the acrylic adhesive and silicone adhesive are present in a ratio of from about 1:2 to about 1:6 claim 3 , based on the total weight of the acrylic and silicone adhesives.8. The transdermal drug delivery system of claim 1 , wherein the polymer matrix comprises an amount of estradiol effective to deliver a therapeutically effective amount of estradiol over a period of time selected from the group consisting of at least ...

Подробнее
20-06-2013 дата публикации

Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation

Номер: US20130156829A1
Принадлежит: TORAY INDUSTRIES INC

A coating agent for a pharmaceutical solid preparation imparts an unpackaged pharmaceutical solid preparation with excellent barrier properties equivalent to those of a PTP sheet without affecting the disintegration properties of the pharmaceutical solid preparation. The coating agent for a pharmaceutical solid preparation includes a polyethylene glycol having an average molecular weight of 950 to 25,000 and a swelling clay, wherein the mass ratio of the polyethylene glycol and the swelling clay is 2:8 to 6:4.

Подробнее
27-06-2013 дата публикации

Multilayer polymeric drug delivery system

Номер: US20130164347A1
Принадлежит: Individual

The invention relates to a customizable, solvent-free sustained release medical device for wound closure, wound healing, and the sustained release of an active. The device of the invention is composed of at least a polymeric carrier layer and optionally an oxidized regenerated cellulose layer(s). Polymeric barrier layers can be added to modify the release profile (burst, time of release, etc.) of the selected bioactive agent(s).

Подробнее
27-06-2013 дата публикации

PATCH BACKING FOR WATER-BASED PASTY PREPARATION

Номер: US20130164495A1
Принадлежит: TOYOBO CO., LTD.

The present invention relates to a backing for a water-based patch consisting of the following constituents, wherein the backing is excellent in pasty preparation retention and moisture retention, improves the persistence of drug efficacy by inhibiting the sublimation of the drug, gives neither restrained feeling nor rough feeling due to a thin thickness and an excellent elasticity, controls the moisture permeability, gives almost no sticky feeling and thereby gives an excellent feeling in application. A patch backing for a water-based pasty preparation consisting of a laminate, wherein the laminate consists of three layers, a film layer having through-holes is laminated between a nonwoven fabric layer A and a nonwoven fabric layer B, said film layer consists of a resin containing an olefin elastomer, the through-hole area per a hole is 0.02-0.18 mm, and the opening ratio of the through-hole is 1-10%. 1. A patch backing for a water-based pasty preparation consisting of a laminate , wherein the laminate consists of three layers in which a film layer having through-holes is laminated between a nonwoven fabric layer A and a nonwoven fabric layer B , said film layer consists of a resin containing an olefin elastomer , the through-hole area per a hole is 0.02-0.18 mm , and the opening ratio of the through-hole is 1-10%.2. The patch backing for a water-based pasty preparation according to claim 1 , wherein the moisture permeability of the backing is 1000-5500 g/m·24 hours.3. The patch backing for a water-based pasty preparation according to claim 1 , wherein the 50% stretch recovery ratio is 70%-100% claim 1 , the basis weight is 50-140 g/m claim 1 , and the thickness is 0.2-0.8 mm.4. The patch backing for a water-based pasty preparation according to claim 1 , wherein the nonwoven fabric layer A and the nonwoven fabric layer B consist of an olefin resin.5. The patch backing for a water-based pasty preparation according to claim 1 , wherein the nonwoven fabric layer A and ...

Подробнее
27-06-2013 дата публикации

PATCH PREPARATION

Номер: US20130165876A1
Принадлежит: NITTO DENKO CORPORATION

The present invention relates to a patch preparation having a central part and a peripheral part surrounding the central part, the patch preparation comprising: a patch preparation main body having a support and an adhesive layer which contains a drug and is formed on the support; and a release liner laminated on the adhesive layer, wherein the peripheral part has a predetermined area, and a peel force between the adhesive layer and the release liner in the predetermined area is greater than a peel force between the adhesive layer and a release liner in the central part. 1. A patch preparation having a central part and a peripheral part surrounding the central part , the patch preparation comprising: a patch preparation main body having a support and an adhesive layer which contains a drug and is formed on the support; and a release liner laminated on the adhesive layer , wherein the peripheral part has a predetermined area , and a peel force between the adhesive layer and the release liner in the predetermined area is greater than a peel force between the adhesive layer and a release liner in the central part.2. The patch preparation according to claim 1 , wherein the patch preparation has a substantially rectangular or a substantially square planar shape.3. The patch preparation according to claim 2 , wherein the peripheral part has four corner areas claim 2 , and the predetermined area is at least one of the four corner areas.4. The patch preparation according to claim 2 , wherein the peripheral part has four corner areas and the predetermined area is one pair of two countering corner areas out of the four corner areas.5. The patch preparation according to claim 2 , wherein the peripheral part has four corner areas claim 2 , and the predetermined area is the four corner areas.6. The patch preparation according to claim 2 , wherein the peripheral part has four sides claim 2 , and the predetermined area is an area along one side out of the four sides.7. The patch ...

Подробнее
04-07-2013 дата публикации

Topical formulations for the prevention of sexually transmitted disease and methods of producing the same

Номер: US20130171089A1
Принадлежит: CLJI IP COMPANY, LLC

The present invention is directed towards various topical protective formulations which may be used as an adjunct in preventing the spread of a broad range of sexually transmitted diseases. The product is intended to be used as a topical lotion, cream, emulsion, or the like. The film forming excipients and active ingredients in the following formulations have demonstrated unique skin protective barrier properties with enhanced persistence that inhibits transmission of sexually transmitted diseases.

Подробнее
04-07-2013 дата публикации

High enhancer-loading polyacrylate formulation for transdermal applications

Номер: US20130172428A1
Принадлежит: Alza Corp

A polyacrylate formulation suitable for delivery of drug to through a body surface of an individual. By loading the drug and permeation enhancers at a high concentration into a polyacrylate proadhesive that has inadequate adhesive properties for typical adhesive application on the skin, a formulation with desirable adhesive characteristics and effective therapeutic properties can be made. The proadhesive has higher glass transition temperature than typical pressure sensitive adhesives.

Подробнее
11-07-2013 дата публикации

TRANSDERMAL THERAPEUTIC SYSTEM WITH CHOLINESTERASE INHIBITOR

Номер: US20130177606A1
Принадлежит:

The invention concerns a transdermal therapeutic system with a carbamate cholinesterase inhibitor for the treatment of mild to moderate Alzheimer's disease dementia and/or Parkinson's disease dementia. 1. Transdermal therapeutic system comprising 'at least one carbamate cholinesterase inhibitor as the active ingredient, at least one polyacrylate polymer with free carboxyl groups and at least one polyacrylate polymer with quaternary ammonia groups,', 'an active ingredient reservoir layer which contains'}a silicone-free adhesive layer comprising at least one polyacrylate with free hydroxyl groups;wherein said active ingredient reservoir layer does not contain an antioxidant.2. The transdermal therapeutic system according to wherein said carbamate cholinesterase inhibitor is rivastigmine.3. The transdermal therapeutic system according to wherein said active ingredient in the active ingredient reservoir layer is present in an amount of about of 0.1% to 40% by weight (based on the total weight of the active ingredient reservoir).4. The transdermal therapeutic system according to wherein said adhesive layer further comprises the active ingredient.5. The transdermal therapeutic system according to claim 1 , wherein the at least one carbamate cholinesterase inhibitor has been dissolved or homogenously dispersed in the active ingredient reservoir layer.6. The transdermal therapeutic system according to claim 1 , wherein the active ingredient reservoir layer further comprises up to 15% weight avocado oil and/or palm oil (based on the total weight of the active ingredient reservoir).7. The transdermal therapeutic system according to further comprising at least one excipient in the active ingredient reservoir layer which improves cohesion and/or solubility of the active ingredient.8. The transdermal therapeutic system according to claim 1 , wherein the polyacrylate with quaternary ammonium groups is a copolymer containing ethylacrylate claim 1 , methyl methacrylate and ...

Подробнее
11-07-2013 дата публикации

Preparation Rich in Growth Factor-Based Fibrous Matrices for Tissue Engeering, Growth Factor Delivery, and Wound Healling

Номер: US20130177623A1
Принадлежит:

Activated platelet-rich plasma (aPRP) is electrospun into fibrous matrices which are used to deliver components of aPRP to a site of action in a sustained manner. The electrospun matrices are used, for example, for tissue engineering applications and for the treatment of wounds. 1. An electrospun fiber comprising either or both of platelet-rich plasma (PRP) and activated platelet-rich plasma (aPRP).2. The electrospun fiber of claim 1 , wherein said electrospun fiber further comprises at least one synthetic polymer.3. The electrospun fiber of claim 2 , wherein said at least one synthetic polymer is selected from the group consisting of poly(glycolic acid) (PGA) claim 2 , polycaprolactone (PCL) claim 2 , poly(lactic acid) (PLA) claim 2 , poly(lactic-co-glycolic acid) (PLGA) claim 2 , polydioxanone (PDO) and polyethylene oxide (PEO).4. The electrospun fiber of claim 1 , wherein said electrospun fiber further comprises at least one natural polymer.5. The electrospun fiber of claim 4 , wherein said at least one natural polymer is silk fibroin.6. The electrospun fiber of claim 1 , wherein said electrospun fiber is formed from aPRP.7. A method for the sustained delivery of one or more components of PRP to a patient in need thereof claim 1 , comprising the step ofproviding to said patient a construct comprising electrospun aPRP fibers.8. The method of claim 7 , wherein said one or more components of PRP include a substance selected from the group consisting of platelet-derived growth factor (PDGF) claim 7 , transforming growth factor-β (TGF-β) claim 7 , and RANTES (Regulated upon Activation claim 7 , Normal T-cell Expressed claim 7 , and Secreted) factors.9. The method of claim 7 , wherein said providing step includes applying said construct to a site of injury.10. The method of claim 7 , wherein said PRP is autologous PRP.11. The method of claim 7 , wherein said PRP is allogenic PRP.12. The method of claim 7 , wherein said providing step includes electrospinning said ...

Подробнее
11-07-2013 дата публикации

Disposable skin care device

Номер: US20130178919A1
Автор: Andrew Mcneill
Принадлежит: Ambicare Health Ltd

There is herein described a disposable skin care device. More particularly, there is described a disposable skin care device capable of forming part of a light emitting medical apparatus.

Подробнее
18-07-2013 дата публикации

Wound Healing Device and Method

Номер: US20130183365A1
Принадлежит: STEMNION, INC.

The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof. 116.-. (canceled)17. A wound healing device for healing incisional wounds comprising a suture or knitted mesh which is embedded with a wound healing composition , wherein the wound healing composition consists of protein factors selected from the group consisting of physiologic levels of VEGF , Angiogenin , PDGF , TGFβ2 , TIMP-1 and TIMP-2 that are dissolved in a carrier , wherein the physiologic levels are ˜5-16 ng/mL for VEGF , ˜3.5-4.5 ng/mL for Angiogenin , ˜100-165 pg/mL for PDGF , ˜2.5-2.7 ng/mL for TGFβ2 , ˜0.68 μg/mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2.18. The wound healing device of wherein the suture or knitted mesh is braided.19. The wound healing device of wherein the suture is nonabsorbable or bioerodable and the knitted mesh is bioerodable.20. The wound healing device of wherein the bioerodable suture or knitted mesh is made of polyglycolic acid claim 19 , polyglutamic acid claim 19 , polydioxanone claim 19 , polylactide claim 19 , or caprolactone.21. The wound healing device of wherein the nonabsorbable suture is made of nylon claim 19 , polyester claim 19 , polypropylene or silk.22. The wound healing device of which is contained in a sterile package.23. The wound healing device of wherein the carrier is selected from the group consisting of normal saline claim 17 , PBS claim 17 , lactated Ringer's solution and cell culture medium. This application is a divisional application of U.S. application Ser. No. 13/374,825, filed Jan. 17, 2012 and claims priority under 35 USC §119(e) of U.S. Provisional ...

Подробнее
18-07-2013 дата публикации

LIDOCAINE PATCH AND METHODS OF USE THEREOF

Номер: US20130184351A1
Автор: CIULLO JAMES
Принадлежит: JAR LABORATORIES

This invention is directed to a transdermal delivery patch comprising local anesthetic agent and optionally a permeation enhancement agent for reducing neuropathic pain. 1. A patch for transdermal delivery of lidocaine for reducing pain comprising , a patch comprising a composition comprising a therapeutically effective amount of lidocaine , wherein said amount of lidocaine is less than 4 percent by weight , and wherein said pain is selected from neuropathic pain , osteoarthritis pain , back pain , pain associated with fibromyalgia , pain associated with carpal tunnel syndrome , pain associated with muscle strain , pain associated with muscle sprain or degenerative bone pain , or any combination thereof.2. The patch of claim 1 , wherein said composition further comprises a treatment enhancing amount of a permeation enhancement agent.3. The patch of claim 2 , wherein said permeation enhancement agent is menthol.4. The patch of claim 3 , wherein said treatment enhancing amount of menthol is up to 16 percent by weight.5. The patch of claim 4 , wherein said treatment enhancing amount of menthol is about 3 to 5 percent by weight.6. The patch of claim 1 , wherein said therapeutically effective amount of lidocaine is 3.95 percent by weight.7. The patch of claim 1 , wherein said lidocaine is its pharmaceutically acceptable free base.8. A method for reducing pain in a subject comprising claim 1 , applying on a skin surface of said subject claim 1 , at or near the site of pain claim 1 , a patch comprising a composition comprising a therapeutically effective amount of lidocaine claim 1 , wherein said amount of lidocaine is less than 4 percent by weight claim 1 , and wherein application of said patch provides transdermal delivery of an amount of lidocaine sufficient to reduce said pain in the subject claim 1 , wherein said pain is selected from neuropathic pain claim 1 , osteoarthritis pain claim 1 , back pain claim 1 , pain associated with fibromyalgia claim 1 , pain ...

Подробнее
01-08-2013 дата публикации

SYSTEMS AND METHODS OF ON-DEMAND CUSTOMIZED MEDICAMENT DOSES BY 3D PRINTING

Номер: US20130193621A1
Принадлежит:

Systems and methods of fabricating a customized dose using a medication 3D printer are provided. According to one embodiment, a system is provided that includes a 3D printer that receives prescription dose instructions from a computer or mobile communication device via a network and assembles a customized medication dose according to the prescription dose instructions by selective application of materials stored in a medicament compound container having at least one reservoir containing the materials for assembly. The materials for assembly can be provided to the 3D printer by a master conduit connecting reservoirs in the medicament compound container to the 3D printer. The 3D printer accesses specified amounts of the materials, which include medicament compounds, via the master conduit, and assembles the customized medication dose according to the prescription dose instructions. 1. A method comprising:receiving prescription dose instructions;formulating a customized dose according to the prescription dose instructions; andassembling the customized dose using a medication 3D printer.2. A medication 3D printer system , comprising:a 3D printer,a medicament compound container including at least one reservoir, wherein the least one reservoirs are connected to a conduit to transport a medicament compound or filler material contained therein to the 3D printer, andwherein the 3D printer receives a prescription dose instruction, formulates a customized dose according to the prescription dose instruction, and assembles a customized dose by selective application of the medicament compound and filler material transported over the conduit from the medicament compound container to the 3D printer.3. The medication 3D printer system of claim 2 , wherein the 3D printer receives the prescription dose instructions over a network.4. The medication 3D printer system of claim 2 , further comprising a signal connector to enable communication between the medicament compound container and ...

Подробнее
01-08-2013 дата публикации

PATCH AND METHOD FOR ENHANCING ADHESION FORCE OF THE SAME

Номер: US20130195957A1
Принадлежит: HISAMITSU PHARMACEUTICAL CO., INC.

A patch comprising a support and an adhesive agent layer, wherein the adhesive agent layer comprises at least one selected from the group consisting of tolterodine acetate and salts thereof. 1. A patch , comprising a support and an adhesive agent layer comprising at least one selected from the group consisting of tolterodine acetate and salts thereof.2. The patch according to claim 1 , wherein a total content of the at least one selected from the group consisting of tolterodine acetate and salts thereof is 0.01 to 50% by mass relative to a total mass of the adhesive agent layer.3. The patch according to claim 1 , wherein the adhesive agent layer further comprises at least one selected from the group consisting of tolterodine and salts thereof.4. The patch according to claim 3 , wherein the adhesive agent layer further comprises a (meth)acrylate copolymer comprising in polymerized form vinyl acetate.5. The patch according to claim 4 , wherein a content of the (meth)acrylate copolymer is 5 to 95% by mass relative to the total mass of the adhesive agent layer.6. The patch according to claim 3 , wherein a total content of the at least one selected from the group consisting of tolterodine and salts thereof is 3 to 60% by mass relative to a total mass of the adhesive agent layer.7. The patch according to claim 1 , wherein the at least one selected from the group consisting of tolterodine acetate and salts thereof is derived in the adhesive agent layer from at least one selected from the group consisting of tolterodine and salts thereof.8. A patch claim 1 , comprising a support and an adhesive agent layer claim 1 , wherein the adhesive agent layer comprises:at least one selected from the group consisting of tolterodine and salts thereof;a (meth)acrylate copolymer comprising in polymerized form vinyl acetate; andat least one selected from the group consisting of tolterodine acetate and salts thereof derived from the at least one selected from the group consisting of ...

Подробнее
01-08-2013 дата публикации

Parenteral Formulations Of Dopamine Agonists

Номер: US20130197005A1
Автор: Anthony H. Cincotta
Принадлежит: VEROSCIENCE LLC

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Подробнее
01-08-2013 дата публикации

Trpv1 compounds in a biodegradable polymer carrier

Номер: US20130197094A1
Принадлежит: WARSAW ORTHOPEDIC INC

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of a TRPV1 compound (e.g., capsaicinoid compound) at or near a target site, one can relieve pain caused by diverse sources, including but not limited to, postoperative pain, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Подробнее
08-08-2013 дата публикации

SYSTEMS AND KITS FOR THE FABRICATION OF TISSUE PATCHES

Номер: US20130202656A1
Автор: Ericson Daniel Grant
Принадлежит: Dynasil Biomedical Corporation

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. 1. A kit , comprising:a syringe configured to receive a quantity of a liquid-containing composition comprising fibrin and/or fibrinogen;a filter configured to separate at least a portion of fibrin and/or fibrinogen within the liquid-containing composition from at least a portion of a liquid component of the liquid-containing composition; anda curing agent capable of activating the polymerization of fibrinogen to fibrin.2. A kit , comprising:a filter comprising a plurality pores;a liquid-containing composition comprising fibrin and/or fibrinogen; anda curing agent comprising thrombin.3. A system for producing a tissue patch , comprising:a syringe configured for containing a quantity of a liquid-containing composition comprising fibrin and/or fibrinogen, and containing a curing agent capable of activating the polymerization of fibrinogen to fibrin; anda filter configured to separate at least a portion of fibrin and/or fibrinogen within the liquid-containing composition from at least a portion of a liquid component of the liquid-containing composition, whereinthe filter is contained within the syringe and/or attached to a discharge port of the syringe.4. The kit of claim 1 , wherein the syringe claim 1 , filter claim 1 , and curing agent are sterile.5. The kit of claim 1 , wherein the liquid-containing composition comprising fibrin and/or fibrinogen comprises blood or a blood component from a subject.6. The kit of claim 1 , wherein the curing agent comprises thrombin and/or a calcium-containing compound.7. The kit of claim 6 , wherein the curing agent comprises a solution containing calcium ions.8. The kit of claim 6 , wherein the curing agent comprises a calcium salt.9. The kit of claim 8 , wherein the calcium salt ...

Подробнее
08-08-2013 дата публикации

Personal Towelette with Cooling Composition for Relief of Heat Symptoms

Номер: US20130202668A1
Принадлежит:

A cooling composition impregnated on a personal towelette which provides a cooling sensation to the body when wiped across the skin. The application of the towelette containing the cooling composition reduces the symptoms of heat due to hot flashes due to menopause, physical exertion, or high temperatures. The composition provides effective cooling but is mild to the skin since it contains active ingredients in combination with skin soothing compounds. The cooling composition of the present invention is made of a combination of natural herbs and botanicals specifically selected to provide synergistic cooling effects. 1. A personal towelette impregnated with a composition of herbs and botanicals for use in relief of heat symptoms caused by hot flashes in peri-menopausal women , physical exertion , or high temperatures , the composition comprising:an effective amount of witch hazel double distilled extract;an effective amount of ethanol with menthol crystals;an effective amount of a Cooling Blend composition of glycerin and botanical extracts and oils; andan effective amount of a Citrus Soft fragrance.2. The composition of wherein the Cooling Blend composition comprises: Glycerin claim 1 , Aloe Vera claim 1 , Arnica claim 1 , Sea Weed Extracts claim 1 , Chamomile Flower Extract claim 1 , Lemon Peel Extract claim 1 , Red Clover claim 1 , Oat Kernel Extract claim 1 , Flaxseed claim 1 , Fennel claim 1 , Wild Yam claim 1 , Tea Tree Oil claim 1 , Cucumber claim 1 , Spearmint claim 1 , Lemon Grass claim 1 , and White Tea Leaf.3. The composition of wherein the ethanol with menthol crystals is SDA 38B-14 claim 1 , 190 proof.4. The composition of wherein the components are provided in proportions comprising: Witch Hazel Double Distilled Extract 44-60% claim 1 , SDA 38B-14 36-52% claim 1 , Citrus Soft Fragrance 0.1-1.0% claim 1 , and Cooling Blend composition 1-15%. This application claims the benefit under Title 35 United States Code §119(e) of U.S. Provisional Application No. ...

Подробнее
08-08-2013 дата публикации

TISSUE PATCH

Номер: US20130202674A1
Автор: Ericson Daniel Grant
Принадлежит: Dynasil Biomedical Corporation

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. 1. A patch , comprising:a primer region comprising a resin; anda solid matrix comprising fibrin and/or fibrinogen positioned over at least a portion of the primer region,wherein the patch is sterile and configured for application to a tissue surface.2. A patch , comprising:a primer region comprising a metal oxide, a metalloid oxide, and/or a zinc-containing composition; anda solid matrix comprising fibrin positioned over at least a portion of the primer region,wherein the patch is configured for application to a tissue surface.3. A patch , comprising: ["the unsupported solid matrix has a Young's modulus of about 10 GPa or less after sterilization using gamma radiation at an intensity of 30 kGy, and wherein", 'the patch is sterile and configured for application to a tissue surface., 'an unsupported solid matrix formed of fibrin and/or fibrinogen, wherein4. A patch , comprising: the fibrin within the unsupported solid matrix is cross-linked to a degree such that, after submerging the unsupported solid matrix in an 8M aqueous solution of urea at 25° C., the unsupported solid matrix retains its structural integrity over a period of at least about 2 hours, and', 'the patch is sterile and configured for application to a tissue surface., 'an unsupported solid matrix formed of fibrin and/or fibrinogen, wherein5. A patch , comprising: the fibrin within the unsupported solid matrix is cross-linked to a degree such that, after submerging the unsupported solid matrix in a 6M aqueous solution of urea at 25° C., the unsupported solid matrix retains its structural integrity over a period of at least about 2 hours, and', 'the patch is sterile and configured for application to a tissue surface., 'an unsupported solid matrix ...

Подробнее
08-08-2013 дата публикации

PATCH

Номер: US20130202677A1
Принадлежит: Sekisui Medical Co. Ltd

Provided is a patch that ensures high storage stability of donepezil or a salt thereof and allows stable transdermal administration of the donepezil or salt thereof in an amount that provides a pharmaceutical effect. The patch includes a substrate and an adhesive layer stacked on and integrated with one surface of the substrate and containing donepezil or a salt thereof and an acrylic adhesive containing a copolymer obtained by copolymerizing monomers that each contain a (meth)acrylic acid ester of a saturated aliphatic alcohol and do not contain vinylpyrrolidone. 1. A patch comprising a substrate and an adhesive layer stacked on one side of the substrate and integrated therewith , the adhesive layer containing donepezil or a salt thereof and an acrylic adhesive containing a copolymer obtained by copolymerizing monomers that each contain a (meth)acrylic acid ester of a saturated aliphatic alcohol and do not contain vinylpyrrolidone.2. The patch according to claim 1 , wherein the adhesive layer contains claim 1 , as a resolvent claim 1 , at least one compound selected from the group consisting of an ester of a saturated aliphatic carboxylic acid with a saturated aliphatic alcohol claim 1 , a saturated aliphatic alcohol claim 1 , and a saturated aliphatic carboxylic acid.3. The patch according to claim 2 , wherein the adhesive layer contains claim 2 , as the resolvent claim 2 , at least one compound selected from the group consisting of a diester of a saturated aliphatic carboxylic acid with a saturated aliphatic alcohol and a triester of a saturated aliphatic carboxylic acid with a saturated aliphatic alcohol.4. The patch according to claim 3 , wherein the diester of a saturated aliphatic carboxylic acid with a saturated aliphatic alcohol is a diester of a saturated aliphatic dicarboxylic acid with a saturated aliphatic alcohol.5. The patch according to claim 3 , wherein the triester of a saturated aliphatic carboxylic acid with a saturated aliphatic alcohol is a ...

Подробнее
15-08-2013 дата публикации

STIFFENER FOR USE WITH A DRUG PATCH

Номер: US20130211347A1
Автор: Arbel Giora, Bar-El Yossi
Принадлежит:

Apparatus and methods are provided including a patch assembly () configured to deliver a substance through a subject's skin. A frame () surrounds at least in part an open portion of the patch assembly, such that a region of the skin is exposed through the open portion when the frame is placed on the skin. A substance support area () is foldably coupled to the frame at a foldable joint (). A substance delivery area () is adapted to be placed in contact with at least a portion of the region of skin, by the substance support area being folded with respect to the frame. A stiffener (), disposed on the substance support area between the foldable joint and the substance delivery area, is configured to facilitate the placement of the substance delivery area on the portion of the region of skin. Other applications are also described. 1. An apparatus for facilitating delivery of a substance through skin of a subject , comprising: a frame that surrounds at least in part an open portion of the patch assembly, such that a region of the skin is exposed through the open portion when the frame is placed on the skin;', 'a substance support area that is foldably coupled to the frame at a foldable joint; and', 'a substance delivery area disposed on the substance support area, and comprising the substance, the substance delivery area being adapted to be placed in contact, through the open portion, with at least a portion of the region of the skin, by the substance support area being folded with respect to the frame; and, "a patch assembly configured to deliver the substance through the skin by being placed on the subject's skin, the patch assembly comprising:"}a stiffener disposed on a region of the substance support area between the foldable joint and the substance delivery area, configured to facilitate the placement of the substance delivery area on the portion of the region of the skin.2. The apparatus according to claim 1 , wherein the stiffener is configured to reduce folding of ...

Подробнее
15-08-2013 дата публикации

Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine

Номер: US20130211351A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient (1r,4r)-6′-fluro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4-b]indol]-4-amine or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer. 1. A pharmaceutical patch for transdermal administration of the pharmacologically active ingredient (1r ,4r)-6′-fluoro-N ,N-dimethyl-4-phenyl-4′ ,9′-dihydro-3′H-spiro[cyclohexane-1 ,1′-pyrano[3 ,4-b]indol]-4-amine or a physiologically acceptable salt thereof , the patch comprising a surface layer , an adhesive layer , and a removable protective layer , wherein the adhesive layer is located between the surface layer and the removable protective layer.2. The pharmaceutical patch according to claim 1 , wherein the adhesive layer comprises at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch.3. The pharmaceutical patch according to claim 2 , wherein the concentration of the pharmacologically active ingredient in the adhesive layer is within the range of from 0.01 to 10 g/mand/or within the range of from 0.01 to 10 wt.-% claim 2 , relative to the total weight of the adhesive layer.4. The pharmaceutical patch according to claim 1 , wherein the surface layer has a thickness within the range of from 0.1 to 5000 μm and/or the adhesive layer has a thickness within the range of from 1.0 to 1000 μm.5. The pharmaceutical patch according to claim 1 , wherein the adhesive layer comprises a pressure sensitive adhesive selected from the group consisting of polysilicone based pressure sensitive adhesives claim 1 , polyacrylate based pressure sensitive adhesives claim 1 , polyisobutylene based pressure sensitive adhesives claim 1 , and styrenic rubber ...

Подробнее
22-08-2013 дата публикации

PREPARATION OF ORODISPERSIBLE FILMS

Номер: US20130216594A1
Принадлежит: HEXAL AG

The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the solvent or solvent mixture, the step of adding at least one gel former to the suspension, the at least one gel former being swellable in the solvent or solvent mixture, and, optionally, the step of swelling the suspension. 1. A method for preparing a pharmaceutical composition for oral administration comprising the steps of:(i) forming a suspension of at least one pharmaceutical ingredient (A) and a solvent or a solvent mixture (B), wherein the at least one pharmaceutical ingredient (A) is poorly soluble or insoluble in the solvent or solvent mixture (B),(ii) adding at least one gel former (C) to the suspension, wherein the at least one gel former (C) is swellable in the solvent or solvent mixture (B) and, optionally(iii) allowing the suspension to swell.2. The method according to claim 1 , further comprising the steps of:(iv) forming a film of the suspension obtainable from step (ii) or step (iii) and(v) drying the film.3. The method according to claim 1 , further comprising adding of at least one further substance selected from the group consisting of flavoring agent claim 1 , sweetener and plasticizer claim 1 , wherein said at least one further substance is readily soluble in the solvent or solvent mixture (B).4. The method according to claim 1 , whereinthe pharmaceutical ingredient (A) is a pharmaceutically active ingredient or a mixture comprising at least one pharmaceutically active ingredient.5. Method The method according to claim 1 , whereinthe at least one pharmaceutical ingredient (A) is between 10% and 80% by weight, andthe gel former (C) is between 5% and 25% by weight,each related to the dry weight of the composition. ...

Подробнее
22-08-2013 дата публикации

Oral pharmaceutical film formulation for bitter tasting drugs

Номер: US20130217697A1
Принадлежит: HEXAL AG

The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s).

Подробнее
29-08-2013 дата публикации

Sublingual films

Номер: US20130225626A1
Принадлежит: ARx LLC, Cynapsus Therapeutics Inc

The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Подробнее
29-08-2013 дата публикации

Self-destructing transdermal therapeutic system having improved functionality and efficacy

Номер: US20130226108A1
Автор: MAIER Stefan, Wirz Margit
Принадлежит: LTS Lohmann Therapie-Systeme AG

The invention relates to a self-destructing transdermal therapeutic system (TTS), preferably in the form of a transdermal patch, that includes an active ingredient, an agent rendering the active ingredient useless, and a perforation mechanism. The perforation mechanism allows a mobile phase to reach the agent that is capable of rendering the active ingredient useless after removing the TTS after use. The agent then comes into contact with the active ingredient and destroys the active ingredient in the presence of the mobile phase. 1. A method of self-destroying a transdermal therapeutic system comprisingproviding a transdermal therapeutic system comprising at least one active ingredient, at least one agent which makes the active ingredient useless, at least one separation layer permeable to liquids but impermeable to solids between the active ingredient and the agent which makes the active ingredient useless, and at least one mechanical means for perforation adjacent a liquid impermeable layer, said mechanical means for perforation possessing a blunt outer contour and a sharp or pointed internal region,applying the transdermal therapeutic system to a patient's skin;removing the transdermal therapeutic system from the patient's skin and thereby perforating the liquid impermeable layer with the sharp or pointed internal region of the mechanical means for perforation, said perforating step ensuring that a mobile phase can approach the agent which makes the active ingredient useless, andcontacting the active ingredient and the agent which makes the active ingredient useless with one another, thereby destroying the active ingredient by this contact.2. The method of self-destroying a transdermal therapeutic system as claimed in claim 1 , wherein the method further comprises activating the agent which snakes the active ingredient useless via the mobile phase.3. The method of self-destroying a transdermal therapeutic system as claimed in claim 1 , wherein the method further ...

Подробнее
12-09-2013 дата публикации

Felbinac-Containing External Patch

Номер: US20130236516A1
Автор: Inoo Katsuyuki
Принадлежит: TEIKOKU SEIYAKU CO., LTD.

Provided is a felbinac-containing external patch which can exhibit high drug release properties, low skin irritation, and high drug stability, wherein felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including a styrene-isoprene-styrene block copolymer, an alicyclic saturated hydrocarbon resin, a softener, and diethyl sebacate, and does not contain L-menthol. Specifically, in the felbinac-containing external patch, 0.1 to 10% by weight of felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base including 10 to 30% by weight of a styrene-isoprene-styrene block copolymer, 10 to 50% by weight of an alicyclic saturated hydrocarbon resin, 10 to 75% by weight of a softener, and 0.1 to 10% by weight of diethyl sebacate. 1. A felbinac-containing external patch wherein felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base comprising a styrene-isoprene-styrene block copolymer , an alicyclic saturated hydrocarbon resin , a softener , and diethyl sebacate , and does not contain L-menthol.2. A felbinac-containing external patch wherein 0.1 to 10% by weight of felbinac having an average particle diameter of 5 μm or more and less than 100 μm is dispersed and mixed in an adhesive base comprising 10 to 30% by weight of a styrene-isoprene-styrene block copolymer , 10 to 50% by weight of an alicyclic saturated hydrocarbon resin , 10 to 75% by weight of a softener , and 0.1 to 10% by weight of diethyl sebacate , and does not contain L-menthol. The present invention relates to an anti-inflammatory analgesic external preparation having percutaneous absorption properties, and in particular, a felbinac-containing anti-inflammatory analgesic external patch which exhibits good drug release properties, low skin irritation, and high drug stability.Felbinac (4-biphenylacetic acid) is ...

Подробнее
12-09-2013 дата публикации

Materials and methods for delivering compositions to selected tissues

Номер: US20130236518A1
Принадлежит: UNIVERSITY OF CALIFORNIA

This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.

Подробнее
19-09-2013 дата публикации

Drug Depots Having Different Release Profiles for Reducing, Preventing or Treating Pain and Inflammation

Номер: US20130243844A1
Автор: William F. Mckay
Принадлежит: WARSAW ORTHOPEDIC INC

Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.

Подробнее
19-09-2013 дата публикации

PRESS-CONTACT TYPE IMMERSING INTERLAYER TISSUE

Номер: US20130243846A1
Автор: ZHAO Dezheng
Принадлежит:

A press-contact type soaked interlayer tissue includes face towel sheets. The face towel sheet comprises two layers of face towel sheet parts (), () and hollow balls (),wherein the shell wall of the hollow ball is made of organic degradable plastics film The shell wall of the hollow ball () is in fully enclosed condition and the hollow ball has spherical or elliptic shape. The respective surrounding inner wall surfaces of the two layers of face towel sheet parts (), () are connected with each other by adhering. The two layers of face towel sheet parts (), () are made of tissue-paper or non-woven fabrics. The hollow balls () are arranged between the two layers of face towel sheet parts (), () in matched manner. Liquid () nontoxic to human skin is sealed in the hollow balls (). 1. A press-contact type of immersing interlayer tissue , including facial tissue , which is characterized by using two layers of facial tissue and hollow balls made of an organic degradable plastic thin film shell in its construction; the shell of said hollow ball is completely enclosed and it is either spherical or elliptical in shape; peripheral inner walls of said two facial tissue layers are adhered to each other and said tissue layers are made of tissue paper or non-woven fabric; said hollow balls are evenly distributed between said two tissue layers; and said hollow balls are filled with a liquid that is nontoxic to the human skin.2. The press-contact type of immersing interlayer tissue as described in claim 1 , further characterized by the fact that said liquid is purified water claim 1 , perfume claim 1 , disinfectant claim 1 , hand sanitizer claim 1 , washing liquid or alcohol.3. The press-contact type of immersing interlayer tissue as described in claim 1 , further characterized by the fact that each hollow ball may be spherical in shape and has a diameter of 2-8 mm claim 1 , or it may be elliptically shaped with a longest diameter of 3-9 mm.4. The press-contact type of immersing ...

Подробнее
19-09-2013 дата публикации

ACTIVATED CREATININE AND PRECURSORS THEREOF AS ANTIBACTERIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING SUCH AGENTS AND USE THEREOF

Номер: US20130243847A1

Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few. 1. A wound dressing comprising an antibacterially effective amount of an antibacterial composition comprising an active agent selected from the group of antibacterially-activated creatinine , a pharmaceutically acceptable salt of said antibacterially-activated creatinine , a precursor of antibacterially-activated creatinine , a pharmaceutically acceptable salt of said precursor or a mixture of said antibacterial agents , said antibacterial composition being admixed with an adhesive composition , comprising at least one finely divided or granular , water-soluble and/or water-swellable absorbent material dispersed in an elastomer , said adhesive composition optionally including a tackifier , and a layer of the antibacterial composition-adhesive composition admixture is supported on a water-insoluble film.2. The wound dressing of claim 1 , wherein said active agent comprises from about 3% to about 99.5% of the total weight of said antibacterial composition.3. The wound dressing of claim 1 , wherein said active agent comprises from about 3% to about 28% of the total weight of said antibacterial composition.4. The wound dressing of claim 1 , wherein said absorbent material comprises at least one of sodium carboxymethylcellulose claim 1 , pectin and gelatin.5. The wound dressing of claim 1 , wherein said elastomer comprises at least one of polyisobutylene claim 1 , isobutylene copolymers (e.g. claim 1 , butyl rubber) claim 1 , polyisoprene claim 1 , nitrile rubber (NBR) and claim 1 , optionally claim 1 , ...

Подробнее
19-09-2013 дата публикации

Pharmaceutical Formulation Containing Gelling Agent

Номер: US20130245055A1

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Подробнее
19-09-2013 дата публикации

Method and Apparatus for Alcohol Administration and Therapeutic Treatments Using Same

Номер: US20130245577A1
Принадлежит: Individual

The present invention provides a method and apparatus for the administration of alcohol to a person, and therapeutic treatments utilizing the method and apparatus. The invention provides an alcohol “patch” in the form of an adhesive patch or bandage-like structure bearing a quantity of alcohol for transdermal delivery to the user. Permeation enhancers, either chemical or structural, may be included to facilitate the penetration of the alcohol through the skin, and for increased efficacy of delivery of the alcohol to the bloodstream of the user.

Подробнее